A comparative trial of a controlled-release formulation of ketoprofen (‘Oruvail’) and a conventional capsule formulation of ketoprofen (‘Orudis’) in patients with osteoarthritis of the hip

Conformational study of ketoprofen by combined DFT calculations and Raman spectroscopy

“…Ketoprofen's half-life in blood plasma was found to be between 2 and 3 h (Martindale, 1996). This short half-life, coupled to the low single administration dosage necessary, renders ketoprofen a very good candidate for the formulation of controlled release dosage forms (Caruso et al, 1982;Houghton et al, 1984a,b;Marcolongo et al, 1984;Morley et al, 1984;Giunchedi et al, 1991;Le Liboux et al, 1994;Habib and Meuse, 1995;Khan et al, 1996;Parejo et al, 1998;Vergote et al, 2001;Roda et al, 2002;Palmieri et al, 2002;Vueba et al, 2004). However, the exact nature of the mechanisms underlying drug controlled release processes is still unknown.…”

New Aspects of Treating Chronic Pain: Multicenter, Open-Label Clinical Trial of Medication Ketonal Duo in Patients With Degenerative Joint Diseases

“…Он эффективен более чем у 98% больных, не вызывает тяжелых НР, не влияет на уровень АД и ЧСС. Лучшую переносимость данной формы кетопрофена по сравнению с обычной отмечали и зарубежные авторы при сравнительном исследовании переносимости обеих форм [31]. По мнению врача и больных, препарат удобен для приема, так что комплаентность при назначении КТД весьма высока (около 98%), а основной причиной пропуска приема препарата было отсутствие боли.…”

Conventional and Novel Pharmaceutical Dosage Forms on Prevention of Gastric Ulcers

“…Minor haematological and biochemical changes during treatment were noted but these were not of clinical importance. Six patients, 2 receiving the controlled-release and 4 receiving the ordinary formulation of ketoprofen, were withdrawn because of lack of efficacy or unacceptable side-effects (120). A multi-centre, double-blind, crossover study was carried out in 80 patients with rheumatoid arthritis to compare the efficacy and side-effect profiles of two formulations of indomethacin.…”